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Summary 
Background: Pantothenate kinase-associated neurodegeneration (PKAN) is a rare genetic disorder 
characterised by progressive generalised dystonia and brain iron accumulation. We assessed 
whether the iron chelator deferiprone can reduce brain iron and slow disease progression. 
Methods: We did an 18-month, randomised, double-blind, placebo-controlled trial 
(TIRCON2012V1), followed by a pre-planned 18-month, open-label extension study, in patients 
with PKAN in four hospitals in Germany, Italy, England, and the USA. Patients aged 4 years or 
older with a genetically confirmed diagnosis of PKAN, a total score of at least 3 points on the 
Barry-Albright Dystonia (BAD) scale, and no evidence of iron deficiency, neutropenia, or abnormal 
hepatic or renal function, were randomly allocated (2:1) to receive an oral solution of either 
deferiprone (30 mg/kg per day divided into two equal doses) or placebo for 18 months. 
Randomisation was done with a centralised computer random number generator and with 
stratification based on age group at onset of symptoms. Patients were allocated to groups by a 
randomisation team not masked for study intervention that was independent of the study. Patients, 
caregivers, and investigators were masked to treatment allocation. Co-primary endpoints were the 
change from baseline to month 18 in the total score on the BAD scale (which measures severity of 
dystonia in eight body regions) and the score at month 18 on the Patient Global Impression of 
Improvement (PGI-I) scale, which is a patient-reported interpretation of symptom improvement. 
Efficacy analyses were done on all patients who received at least one dose of the study drug and 
who provided a baseline and at least one post-baseline efficacy assessment. Safety analyses were 
done for all patients who received at least one dose of the study drug. Patients who completed the 
randomised trial were eligible to enrol in a single-arm, open-label extension study of another 18 
months, in which all participants received deferiprone with the same regimen as the main study. 
The trial was registered on ClinicalTrials.gov, number NCT01741532, and EudraCT, number 2012-
000845-11. 
Findings: Following a screening of 100 prospective patients, 88 were randomly assigned to the 
deferiprone group (n=58) or placebo group (n=30) between Dec 13, 2012, and April 21, 2015. Of 
these, 76 patients completed the study (49 in the deferiprone group and 27 in the placebo group). 
After 18 months, the BAD score worsened by a mean of 2·48 points (SE 0·63) in patients in the 
deferiprone group versus 3·99 points (0·82) for patients in the control group (difference –1·51 
points, 95% CI –3·19 to 0·16, p=0·076). No subjective change was detected as assessed by the PGI-
I scale: mean scores at month 18 were 4·6 points (SE 0·3) for patients in the deferiprone group 
versus 4·7 points (0·4) for those in the placebo group (p=0·728). In the extension study, patients 
continuing deferiprone retained a similar rate of disease progression as assessed by the BAD scale 
(1·9 points [0·5] in the first 18 months vs 1·4 points [0·4] in the second 18 months, p=0·268), 
whereas progression in patients switching from placebo to deferiprone seemed to slow (4·4 points 
[1·1] vs 1·4 points [0·9], p=0·021). Patients did not detect a change in their condition after the 
additional 18 months of treatment as assessed by the PGI-I scale, with mean scores of 4·1 points 
[0·2] in the deferiprone–deferiprone group and of 4·7 points [0·3] in the placebo–deferiprone group. 
Deferiprone was well tolerated and adverse events were similar between the treatment groups, 
except for anaemia, which was seen in 12 (21%) of 58 patients in the deferiprone group, but was 
not seen in any patients in the placebo group. No patient discontinued therapy because of anaemia, 
and three discontinued because of moderate neutropenia. There was one death in each group of the 
extension study and both were secondary to aspiration. Neither of these events was considered 
related to deferiprone use. 
Interpretation: Deferiprone was well tolerated, achieved target engagement (lowering of iron in the 
basal ganglia), and seemed to somewhat slow disease progression at 18 months, although not 
significantly, as assessed by the BAD scale. These findings were corroborated by the results of an 
additional 18 months of treatment in the extension study. The  
 
 
  
Introduction 
Neurodegeneration with brain iron accumulation (NBIA) is a clinically and genetically heterogeneous 
group of rare hereditary neurodegenerative disorders characterised by high concentrations of brain 
iron.1 Around 50% of cases are due to pantothenate kinase-associated neurodegeneration (PKAN), 
caused by mutations in the pantothenate kinase 2 (PANK2) gene.2 The PANK2 enzyme localises to 
mitochondria and is essential for the biosynthesis of coenzyme A, which in turn is vital for ATP 
synthesis and fatty acid and neurotransmitter metabolism. Absence or abnormal function of PANK2 
can contribute to iron accumulation in specific brain regions.3 The time of onset of clinical signs 
ranges from infancy to adulthood, progression ranges from rapid to slow, and symptoms can vary 
greatly. Disease characteristics include progressive dystonia, parkinsonism, rigidity, and spasticity. 
The factors that influence disease severity and progression rate of PKAN are unknown. No disease-
modifying therapies are yet available in PKAN or any form of NBIA.4–6 Historically, PKAN has been 
described as either classic or atypical. In classic PKAN, symptoms usually develop before 6 years of 
age, and most patients require a wheelchair by their mid-teens. Atypical PKAN usually becomes 
evident after 10 years of age, is less severe, and progresses more slowly than classic PKAN.3,7 It is 
hypothesised that classic PKAN results from complete absence of the PANK2 enzyme, whereas 
atypical disease results from severe deficiency.3 
Although iron is essential for normal physiological function, an excessive amount or dysregulated 
iron metabolism is potentially toxic. Increased free iron in tissues leads to the formation of highly 
reactive oxygen species, causing localised toxicity.8,9 Although proof that iron causes 
neurodegeneration in PKAN and most other NBIAs is insufficient, preferential iron accumulation in 
the basal ganglia probably explains the predominant phenotype of this movement disorder.10 
Accordingly, iron chelation holds the potential to decrease brain iron concentrations in NBIA, which 
could retard disease progression.  
Deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one) is an oral iron chelator approved for the 
treatment of transfusional iron overload in patients with thalassaemia. Deferiprone crosses the blood–
brain barrier, chelates excess iron from intracellular organelles, and can transfer it to biological 
receptors, such as transferrin.11 Few safety and efficacy data exist on patients with brain iron 
accumulation. On the basis of the available data in patients with PKAN or other neurodegenerative 
disorders who received deferiprone,6,12–20 it was hypothesised that deferiprone could reduce brain 
iron, which might lead to clinical benefit. We aimed to assess whether deferiprone could reduce the 
clinical symptoms of PKAN or slow its progression. This Article describes the results of the 
TIRCON2012V1 study, which is, to our knowledge, the first randomised clinical trial of a putative 
therapeutic drug in patients with PKAN, and of its single-arm extension study, TIRCON2012V1-
EXT. 
 
Methods  
Key information on study methods is provided here, and further details are available in the appendix 
(p 1).  
Study design  
TIRCON2012V1 was an 18-month, multicentre, randomised, double-blind, placebo-controlled trial 
that evaluated the safety and efficacy of deferiprone in patients with PKAN in four hospitals in 
Germany, Italy, England, and the USA. Patients who completed the randomised trial were eligible to 
enrol in a single-arm open-label extension study of another 18 months, TIRCON2012V1-EXT, in 
which all participants received deferiprone.  
 
An independent Data and Safety Monitoring Board regularly reviewed the safety data of both trials, 
and each study was registered on ClinicalTrials.gov before enrolment of the first patient. The trial 
was approved by the respective Ethics Committees of the study centres (Ludwig Maximilians 
University, Munich, Germany; Istituto Neurologico Carlo Besta, Milan, Italy; Yorkshire and the 
Humber—Leeds East health research authority, Leeds, UK; and Children’s Hospital and Research 
Center, Oakland, CA, USA).  
Participants  
Patients aged at least 4 years were eligible for enrolment in TIRCON2012V1 if: they had a diagnosis 
of PKAN confirmed by genetic testing; a total score of 3 points or more on the Barry-Albright 
Dystonia (BAD) scale, which ranges from 0 (best) to 32 (worst); and no evidence of iron deficiency, 
neutropenia, or abnormal hepatic or renal function. Exclusion criteria included treatment with any 
iron chelator in the past 12 months and the presence of medical conditions or other indicators that 
might increase safety concerns. The full list of inclusion and exclusion criteria is provided in the 
appendix (p 1). The use of symptomatic treatments for dystonia (eg, baclofen, trihexyphenidyl, 
clonazepam, tizanidine, or botulinum toxin) was permitted; however, to reduce confounds, 
individuals were excluded if they had recent (within 2 months) or anticipated changes in any ongoing 
regimen to treat dystonia (ie, medication or a device for deep brain stimulation). Written informed 
consent was obtained from each participant or the parent or legal guardian before any procedures 
were done.  
Randomisation and masking  
In TIRCON2012V1, patients were assigned (in a 2:1 ratio) to receive either an oral solution of 
deferiprone up to 30 mg/kg per day divided into two doses (deferiprone group) or matching placebo 
(identical packaging, appearance, and taste; placebo group), using block randomisation in block sizes 
of six. Investigators were in charge of confirming eligibility and an independent team was responsible 
for random group assignment. The randomisation list was generated using a computer random 
number generator. A centralised randomisation process was used for all study sites, and patients were 
allocated to groups by an unmasked randomisation team that was independent of the study. Group 
allocation was concealed through a centralised randomisation process with a computer-generated 
randomisation list. Randomisation was stratified on the basis of the patient’s age at onset of motor 
symptoms, with one list generated for individuals who had been younger than 6 years at the onset of 
motor symptoms (classic PKAN) and another list generated for those who had been 6 years or older 
(atypical PKAN). Patients, caregivers, study staff, and the neurologists who analysed videotapes for 
determination of BAD scores were unaware of treatment assignment, as were the radiologists who 
analysed the MRI images to determine iron concentrations in the globus pallidus.  
In the extension trial, all patients received deferiprone. However, since the randomised study was 
still in progress when the extension study began, both patients and staff remained masked to which 
product had been taken for the previous 18 months until both studies had been completed and their 
data locked.  
Procedures  
Participants took the assigned study product twice daily every day for 18 months (appendix p 3). 
Compliance was evaluated at each post-baseline visit by calculating the volume of medication 
dispensed and the amount of unused drug supply remaining in the bottle. Following the baseline visit 
of the main study, patients had safety and efficacy assessments at the following intervals: month 1·5 
(week 6), 3, 6, 12, and 18. Patients were also contacted by phone weekly for the first 6 weeks and 
then on month 2, 9, and 15. During the extension study, patients were contacted by phone weekly 
during the first 2 weeks of the study and then had site visits every 6 months.  
Efficacy assessed every 6 months used the following measures: (1) the BAD scale, which measures 
the severity of dystonia in eight body regions (eyes, mouth, neck, trunk, and each upper and lower 
extremity) and generates individual scores and a total score; (2) the Patient Global Impression of 
Improvement (PGI-I) scale, a subjective instrument which consists of a single question asking 
patients to rate their condition on a scale from 1 (very much better) to 7 (very much worse) compared 
with how they had felt at baseline; (3) parts I, II, III, and VI of the Unified Parkinson’s Disease Rating 
Scale (UPDRS) for assessment of motor symptoms that resemble those of patients with Parkinson’s 
disease, as well as some quality of life aspects; (4) the Functional Independence Measure (FIM) or 
WeeFIM (paediatric version) for assessment of various measures of functional independence; (5) the 
Pediatric Quality of Life (PedsQL) scale for measurement of quality of life; and (6) the Pittsburgh 
Sleep Quality Index (PSQI) for measurement of quality of sleep. For the BAD scale, the required 
tests were done and videotaped at the site, and the videotapes were sent to a central site for masked 
assessment by experts on movement disorders. We do not report the Likert scale here, which was 
mentioned as an efficacy evaluation in our protocol paper, because it overlaps with elements from the 
other scales we used. Iron concentrations in the globus pallidus were measured by MRI-R2* mapping 
in a subset of patients at baseline and month 18. Safety assessments were done at each visit and 
involved collecting data on adverse events, clinical laboratory tests, physical examination, vital signs, 
and electrocardiogram (ECG; at screening and month 18 only).  
In the extension study, patients who had been randomly assigned to deferiprone continued to receive 
it and those who had been assigned to placebo were switched to deferiprone. Again, efficacy 
assessments were made every 6 months. Safety evaluations were the same as in the main trial but 
efficacy measures were made only with the BAD scale and PGI-I.  
Outcomes  
In the randomised trial, the co-primary efficacy endpoints were change from baseline to month 18 in 
the BAD total score and the PGI-I score of improvement from baseline to month 18. The outcome 
was to be considered positive if the group differences in both co-primary endpoints reached 
significance (p<0·05).  
Secondary efficacy endpoints were iron concentrations in the globus pallidus (as assessed by MRI-
R2*), change from baseline to month 18 in the BAD score for each body region (eight regions), the 
FIM or WeeFIM, UPDRS, PedsQL, and PSQI scales, and the proportions of patients at month 18 
with improved or unchanged BAD total scores and PGI-I scores. Blood samples for the 
pharmacokinetic analyses of deferiprone and its main metabolite, deferiprone 3-O-glucuronide, were 
collected from a subset of 13 patients during the month-6 visit, before dosing and at 1, 1·5, 2, 2·5, 3, 
4, 6, 8, and 12 h after dosing. All samples were analysed but pharmacokinetic parameters were 
evaluated only for the patients who were receiving deferiprone (n=9), not for those receiving placebo 
(n=4). The results on pharmacokinetics reported in our study for patients with PKAN receiving 
deferiprone at a dose of 15 mg/kg were similar to what has been previously observed in studies in 
healthy volunteers.21 Wedid not report our results because of this consistency and because of space 
limitations. For the safety endpoints, the intervention groups were compared for their frequency of 
adverse events, frequency of serious adverse events, and number of discontinuations due to adverse 
events.  
In the extension study, the primary endpoint was safety and the efficacy endpoints were change in 
BAD and PGI-I scores.  
Statistical analysis  
At the time of planning the randomised trial, to our knowledge, there were no published studies with 
data sufficient to estimate sample size on the basis of either the natural history of the disease or the 
expected impact from a drug that interfered with iron-related neurodegeneration. An estimate of the 
effect size was based on a retrospective study of 23 patients with NBIA, 22 of whom most probably 
had PKAN (14 genetically confirmed, the others with eye-of-the-tiger sign), and 21 of whom had 
been assessed for dystonia using the BAD scale.22 We assumed that with similar disease progression, 
after 18 months, there could be a substantial worsening of the BAD total score in the control group, 
with a possible difference from the deferiprone group of 5 points or more. Assuming a standard 
deviation of 6·3 points, a randomisation ratio of 2:1, and 30% drop out, 87 patients would be needed 
to detect a difference of at least 5 points at a two-sided 0·05 level of significance with 80% power. 
For the extension study, there was no formal sample size and power calculation; all patients 
completing TIRCON2012V1 were invited to enrol.  
Safety analyses were based on all randomised patients who received at least one dose of the study 
drug. Efficacy analyses were based on the intention-to-treat population, defined as all randomised 
patients who received at least one dose of study drug and provided a baseline and at least one post-
baseline efficacy assessment. A mixed model for repeated measures (MMRM) model was used as the 
primary analysis method to assess the primary and secondary endpoints of changes from baseline to 
the specified timepoints (months 6, 12, and 18), with baseline value and age of onset of motor 
symptoms (before 6 years vs at or after 6 years) as covariates and treatment group as the main factor 
in the model. The marginal mean change (least squares estimate) at month 18 was used to determine 
the treatment effect in the primary analysis. Over the 18-month course of the trial, some participants 
required changes in their settings for deep brain stimulation or in the use or frequency of rescue or 
as-needed medications, and these variables were also included in the MMRM model as visit-
dependent covariates.  
A similar MMRM model was used for the analysis of the PGI-I scale. As the PGI-I score is a 
measurement of change from baseline, it was treated directly as the outcome variable. A logistic 
regression model with similar covariates was used for analysis of the proportion of responders. 
Finally, subgroup analyses using a similarMMRM model were done on the co-primary efficacy 
endpoints on the basis of pre-established factors, such as age at onset of motor symptoms (classic or 
atypical PKAN), use of deep brain stimulation, and use of a baclofen pump. The results are not 
reported in the Article as they were either uninformative because of the small number of patients 
using deep brain stimulation or baclofen pumps, or did not differ from the results of the main analysis. 
The safety data for continuous variables were summarised using descriptive statistics, and the safety 
data for discrete variables were tabulated with frequency tables. The trial was registered with 
ClinicalTrials.gov, number NCT01741532, and EudraCT, number 2012-000845-11.  
In the extension study, changes in the BAD scale and PGI-I scores were summarised using descriptive 
statistics. The last observation carried forward (LOCF) method was used for the scores of patients 
who did not complete treatment. A paired t test was used to compare the change in BAD total score 
and PGI-I score between therandomised and the extension studies, whereas Student’s t test was used 
for within-study comparison of treatment groups. All statistical analyses were done with SAS(version 
9.3). The extension study was registered with ClinicalTrials.gov, number NCT02174848.  
Role of the funding source  
Funding for the study was provided by the European Commission, the US Food and Drug 
Administration, and ApoPharma Inc, Canada. The US FDA had input into the design and selection 
of endpoints. ApoPharma participated in study design, data collection, data analysis, data 
interpretation, and writing of the report. The corresponding author had full access to all data in the 
study and had final responsibility for the decision to submit for publication.  
 
Results  
Following a screening of 100 prospective patients, 89 of 90 planned participants were enrolled 
between Dec 13, 2012, and April 21, 2015. 59 were randomly assigned to receive deferiprone and 30 
to receive placebo (figure 1). One patient assigned to the deferiprone groupwithdrew before receiving 
the first dose because of a medical event, and two assigned to placebo withdrew consent after 
receiving the study drug but before providing any post-baseline efficacy data. Accordingly, there 
were 58 patients in the deferiprone group evaluable for both safety and efficacy, and 30 in the placebo 
group evaluable for safety and 28 for efficacy. 76 (85%) of 89 patients completed the trial and 12 
(excluding the one patient who was never dosed) withdrew: three (10%) in the placebo group and 
nine (15%) in the deferiprone group. Four patients (all in the deferiprone group) withdrew because 
of an adverse event. Of these withdrawals, three were for moderate neutropenia (confirmed absolute 
neutrophil counts ≥ 0·5 × 10⁹ – <1·0 × 10⁹ cells/L), for which withdrawal was mandated by the study 
protocol, and one was for fever and pneumonia.  
At baseline, there were no major differences between the treatment groups with respect to age at 
enrolment, duration of disease, sex, and race, baseline BAD score, or amount of iron in the relevant 
brain areas (table 1). Stratification was used to ensure that each treatment group had approximately 
equal proportions of patients with classic or atypical PKAN, as determined by age at onset of motor 
symptoms. From the 86 patients who were evaluable for efficacy, there were 12 patients with classic 
and 16 with atypical presentation in the placebo group, and 29 with each type in the deferiprone 
group. Mean age at randomisation differed considerably between the subgroups (SD 13·7 years for 
patients with classic and26·5 years for those with atypical PKAN), but disease duration 
(approximately 13 years) was similar for both groups. As we expected, the disease had progressed 
further in patients with classic PKAN, as indicated by baseline BAD scores (20·3 [SD 8·9] vs 17·0 
[7·6]), but the difference was not significant (p=0·075).  
Concomitant treatments for dystonia symptoms were an important consideration because of their 
possible confounding effect on the BAD score. Most participants (18 [60%] patients receiving 
placebo and 42 [72%] patients receiving deferiprone) were taking at least one medication for dystonia 
at baseline; 25 patients (six [20%] and 19 [32%], respectively) had a deep brain stimulation system 
in place; and three patients (one [3%] and two [3%], respectively) had a baclofen pump in place. 
Treatment groups were similar regarding the use of any medication or device for the treatment of 
dystonia at baseline (appendix p 4). 18 (60%) of 30 patients receiving placebo and 42 (72%) of 58 
receiving deferiprone reported taking at least one such medication, with the most common being 
baclofen (14 [47%] of patients in the placebo group and 27 [47%] of patients in the deferiprone 
group), trihexyphenidyl (nine [30%] and 25 [43%]), clonazepam (seven [23%] and 12 [21%]), and 
diazepam (four [13%] and five [9%]). No other medication was being taken by more than four patients 
in a group. During the study, additional dystonia medications administered on an as-needed basis 
were taken by a higher proportion of patients in the placebo group (six [21%]) than patients in the 
deferipronegroup (six [11%]), with the greatest difference between groups for botulinum toxin type 
A.  
Compliance, as assessed by volume of medication taken versus volume prescribed, was very high at 
all timepoints, ranging from 95% to 99% volume taken in the placebo group and from 97% to 99% 
in the deferiprone group.  
One patient in the placebo group had a baseline BAD score of 31 and one in the deferiprone group 
had the maximum score of 32 (table 1), meaning that little or no further worsening could be detected 
in those individuals through this instrument. Further analyses showed that results were not 
confounded by a ceiling effect (appendix p 5). Patients in both treatment groups worsened over time 
(figure 2). In the main analysis, using the marginal means from the MMRM model, the scores of 
patients in the deferiprone group worsened by 2·48 points (SE 0·63) versus 3·99 points (0·82) in the 
placebo group (difference –1·51, 95% CI –3·19 to 0·16, p=0·076; table 2).  
By contrast with the signs of disease progression as assessed by the BAD score, no subjective change 
was detected as assessed by the PGI-I. At month 18, mean PGI-I scores were 4·7 (SE 0·4) for placebo 
and 4·6 [0·3] for deferiprone (difference –0·12, 95% CI –0·80 to 0·56, p=0·728), indicating that 
patients in both groups did not perceive either improvement or worsening since baseline. There was 
only a weak correlation (r=0·29) between the PGI-I and the change in BAD score at month 18 
(appendix p 7).  
A predefined subgroup analysis that assessed separately patients with classic or atypical PKAN 
provided some evidence to show that deferiprone use in patients with atypical PKAN could be 
associated with slower progression of clinical symptoms (2·33 points [0·73]) than the use of placebo 
(4·52 points [0·91]; difference 2·19 points, 95% CI –4·00 to –0·38, p=0·019). In patients with classic 
PKAN, the difference of 0·81 points in favour of deferiprone was not supported by the evidence 
(p=0·570; table 2). In the responder analysis, 20 (36%) patients treated with deferiprone responded 
to therapy, compared with four (14%) patients treated with placebo (p=0·089).  
Iron concentrations in the globus pallidus were measured via MRI-R2* imaging in a subset of patients 
at the start (16 in the placebo group and 24 in the deferiprone group) and end of the study (13 and 19 
patients, respectively). In the placebo group, there was no change in mean iron concentration (mean 
R2* decrease of 0·5 Hz, SE 4·0, 95% CI –8·7 to –7·78), whereas in the deferiprone group, there was 
a significant decrease of 36·1 Hz (3·1, –42·5 to –29·7), difference –35·6 Hz (95% CI –44·8 to –26·3, 
p <0·0001; figure 3).  
Of the 21 measures we examined, although more outcome measures seemed to favour deferiprone 
than placebo, there was weak evidence only in support of adifference between groups for the WeeFIM 
cognition score (difference 6·30, p=0·032) and for BAD scores for specific body regions (neck –0·43, 
p=0·047; left lower extremity –0·28, p=0·039; and right lower extremity –0·25, p=0·044; figure 4). 
Detailed results on the WeeFIM assessments are provided in the appendix (p 8).  
Overall, deferiprone was well tolerated. All but one patient experienced at least one adverse event 
(57 [98%] of patients receiving deferiprone and 30 [100%] of patients receiving placebo). Adverse 
events occurring in more than 10% of patients are shown in table 3. Incidence of these events was 
similar between the treatment groups, except for events directly related to treatment with deferiprone, 
such as anaemia. Six (10%) patients in the deferiprone group had mild anaemia (haemoglobin >11 
g/dL) and six (10%) had moderate anaemia (haemoglobin 8·0–10·9 g/dL). A higher proportion of 
patients in the deferiprone group had mildly lower concentrations of serum ferritin than patients in 
the placebo group (19 [33%] vs five [17%], p=0·134) and had mild iron deficiency (nine [16%] vs 
three [10%], p=0·744; appendix p 10). Iron supplementation as needed was permitted on the basis of 
the investigator’s assessment, and was taken by 23 (40%) of patients in the deferiprone group and by 
eight (27%) in the placebo group. There were no deaths or episodes of agranulocytosis or severe 
neutropenia, and there was no significant difference between the study groups in the incidence of 
mild neutropenia (five [9%] vs two [7%]).  
Of the 76 patients who completed the randomised trial, 68 enrolled in the extension study. Those who 
had received deferiprone continued to receive it (deferiprone– deferiprone group, n=44), whereas 
those who had received placebo were switched to deferiprone (placebo–deferiprone group, n=24). 
All 68 patients were evaluable for safety, and 62 (43 in the deferiprone–deferiprone group and 19 in 
the placebo–deferiprone group) were evaluable for efficacy.  
BAD scores at the start of the extension study are shown in table 1 (at this timepoint, one patient on 
placebo–deferiprone had a score of 30 and one on deferiprone–deferiprone had the maximum score 
of 32). Figure 2 displays the change in BAD total scores for the 62 patients who provided evaluable 
efficacy data in both studies. In both groups, scores continued to increase (worsen) over time, but 
patients in the deferiprone– deferiprone group showed a similar rate of progression in both studies, 
whereas patients in the placebo– deferiprone group progressed more rapidly in the first study and 
slowed when they were switched to deferiprone. Over the 18 months of the extension study, there 
was no significant difference in the change in BAD score for patients who had received deferiprone 
from the start (1·9 points [SE 0·5] in the first 18 months vs 1·4 points [0·4] in the second 18 months, 
p=0·268), while patients in the placebo–deferiprone group worsened significantly more (4·4 points 
[1·1] when they were receiving placebo vs 1·4 points [0·9] when they were receiving deferiprone, 
p=0·021; appendix p 11). With respect to the PGI-I, as in the randomised study, patients did not detect 
a change in their condition after the additional 18 months of treatment, with mean scores of 4·1 [SE 
0·2] in the deferiprone–deferiprone group and of 4·7 [0·3] in the placebo–deferiprone group.  
For evaluation of safety throughout the whole study period, data were combined for all 68 patients. 
Overall, deferiprone was well tolerated for the 36-month period. There were two deaths, both 
secondary to pulmonary aspiration (one from pneumonia and multi-organ failure, the other to 
aspiration following the patient vomiting in his sleep). Neither of these patients had had neutropenia 
while the study was ongoing. The most common adverse event was dystonia, reported in 40 (59%) 
patients, followed by pyrexia in 23 (34%), headache in 20 (29%), and decrease of serum ferritin in 
18 (27%).  
To investigate whether a ceiling effect confounded the results of our study, we did an exploratory 
analysis and repeated the MMRM analysis excluding all patients with a baseline BAD score of less 
than 27 who would potentially be subject to a ceiling effect. In this analysis, patients treated with 
deferiprone showed a numerically lesser progression in BAD scores than patients treated with 
placebo, with the marginal mean difference being similar to that from the analysis of the intention-
to-treat population (appendix p 5). Additional exploratory analysiswas done to compare response to 
treatment according to the tertiles of baseline BAD scores, showing weak evidence for a potential 
benefit of deferiprone versus placebo, although this benefit was not significant.  
 
Discussion  
The data from up to 3 years of deferiprone therapy in patients with PKAN show that its use was well 
tolerated, was associated with a reduction of excess iron in the brain, and was potentially associated 
with some slowing of disease progression. To our knowledge, our study is the largest randomised 
trial to date and provides the longest prospective follow-up of any population with NBIA. It yields 
valuable information about the impact of iron chelation on PKAN, but also on the disease’s natural 
history through the detailed assessment of patients receiving placebo, indicating that the rate of 
disease progression is slower than previously estimated.22 In our trial, the power calculation for the 
divergence in the change in BAD total score between the treatment groups had assumed that a 
clinically relevant difference of 5 points could be achieved; however, over 18 months, the placebo 
group worsened less than we anticipated. Accordingly, the only way a significant group difference 
could have been achieved would have been for deferiprone to reverse rather than slow the progression 
of the disease. It is noteworthy that even the difference of 1·51 points approached the protocol-defined 
criterion for statistical significance. Thus, whether a treatment duration longer than 18 months might 
provide evidence for a treatment effect should be explored.  
We did not exclude patients with high BAD scores for enrolment, which might have led to a ceiling 
effect where patients with high BAD scores (close to the maximum score of 32) at baseline cannot 
worsen as much as patients with lower BAD scores. Randomisation resulted in proportionally more 
patients with high baseline BAD scores being assigned to receive deferiprone. Post-hoc exploratory 
MMRM analyses suggested that the intention-to-treat analysis had not been confounded by a possible 
ceiling effect in patients with high BAD scores, although it was not possible to distinguish whether 
deferiprone was truly beneficial in those patients. In conclusion, these analyses provided evidence 
suggesting that PKAN progression as measured by the BAD score slows with increasing baseline 
values and that this trend leads to a ceiling effect at very high baseline scores. Although this 
information is important for the design of future trials, it did not affect the principal outcome of our 
study. The potential benefit of deferiprone is also supported by the lower use of dystonia medications 
during the trial by patients taking deferiprone than by patients taking placebo, and by the results of 
the extension study. In patients who received deferiprone in both studies, disease progression 
continued at the same rate, whereas in those who switched from placebo to deferiprone, it slowed to 
match the rate seen in those who had received deferiprone in the first study. The fact that the rate of 
deterioration in the placebo–deferiprone group was less (p=0·021) during the 18 months of 
deferiprone treatment than it was during the 18 months of placebo treatment supports the effect of 
this drug in patients acting as their own controls.  
Another factor for consideration is the stage of the disease, since in any neurodegenerative process 
the later the intervention with a drug to slow progression is introduced, the less the expected benefit. 
Participants in this study had been having PKAN symptoms for approximately 13 years at the time 
of enrolment, and it is probable that for many the disease progression was too advanced for a 
preventive drug to provide significant benefit. If brain iron contributes to the pathology seen in 
PKAN,10 then early initiation of deferiprone in patients with less extensive iron-induced 
neurodegeneration would be expected to maximise its benefit in slowing disease progression. Support 
for this view was provided by our predefined subgroup analysis looking separately at patients with 
classic versus atypical PKAN. In atypical PKAN, symptoms appear later and the disease progresses 
more slowly than in classic PKAN.2,7 Hence, although the patients with atypical PKAN had the 
disease for about the same duration as those with classic PKAN, the extent of irreversible 
neurodegeneration would have been lower. This difference might explain why patients with atypical 
PKAN seemed to have a better response than patients on placebo in the randomised portion of the 
study.  
The low prevalence of PKAN (1 to 3 cases per million)22 was responsible for the paucity of patients, 
and, considering the slower than predicted rate of disease progression, an increased number of 
patients could have compensated for inadequate power to reach the pre-set level of significance of 
p<0·05 in the 18-month study. As the conduct of studies larger than ours is improbable, any attempt 
at future clinical trials will probably require patient enrichment for targeted questions.  
With respect to the PGI-I endpoint, most participants reported neither worsening nor improvement 
from baseline despite the indications seen on more objective measures; and the same was true in the 
extension study. The correlation between the PGI-I and the change in BAD score at month 18 was 
weak (r=0·29), in which less than 10% of the variation in PGI-I scores could be explained by the 
change in BAD scores (r²<0·1), indicating that the PGI-I is not an adequate tool for assessment in 
PKAN over an 18-month period. The PGI-I is, by definition, subjective, and was probably 
inappropriate for this study. It might be a good tool for assessing the short-term effect of drugs that 
improve or reverse disease, but it was probably difficult for patients to judge whether their condition 
had worsened or improved over a period as long as 18 months, explaining why no net worsening was 
detected by this measure, even by those on placebo.  
The most notable change observed was the large reduction of iron in the globus pallidus: a mean 
decrease of 36·1 Hz in patients in the deferiprone group compared with 0·50 Hz in the placebo group 
(p<0·0001). Thisfinding is consistent with reports of deferiprone-induced reductions in the 
concentrations of brain iron seen in Friedreich’s ataxia,17 Parkinson’s disease,18 and other NBIA 
disorders.23 Importantly, the reduction in brain iron load induced by deferiprone was not associated 
with systemic iron depletion.  
Freezing of gait, an event commonly observed in PKAN patients, was seen in three (10%) of 30 
patients taking placebo, but in none of those taking deferiprone (p=0·037), although there were twice 
as many patients in the deferiprone group. Freezing has been linked to pathology in the basal ganglia 
and brainstem, both of which are areas affected in PKAN and in which iron was decreased by 
treatment with deferiprone. Further investigation of the mechanism through which deferiprone might 
decrease the clinical manifestations of PKAN is warranted.24  
With respect to other secondary efficacy endpoints of the randomised study, although many of the 
group differences did not reach significance, patients who received deferiprone deteriorated less over 
18 months of treatment than patients on placebo in most outcome measures. Responder analysis (the 
proportion of patients showing either improvement or stabilisation of their total BAD score) found 
that the response was not different between patients receiving deferiprone and those receiving 
placebo. Patients on deferiprone deteriorated less on their individual BAD scores for nearly all body 
regions, with group differences reaching significance (albeit marginal, as they would not be 
significant if multiplicity were considered) for neck, left lower extremity, and right lower extremity.  
After the reduction of brain iron concentrations, the most substantial difference between treatments 
was seen on the WeeFIM measure, where actual improvement—not merely reduced worsening—was 
seen in cognition in patients on deferiprone, with the difference between treatment groups reaching 
significance (p=0·032). No significant group differences were seen on the other secondary measures. 
However, examination of all the secondary endpoints showed a pattern that suggested a beneficial 
effect of deferiprone across a broad range of functions.  
The tolerability of deferiprone was evidenced by the near-total compliance and low number of 
dropouts in both studies. The two deaths were unrelated to study treatment, and adverse events, which 
were mainly mild, were similar between the treatment groups on most measures (table 3, appendix p 
10). In general, the safety findings were consistent with those of other studies of deferiprone in 
patients with both brain iron overload 6,12,25,26 and systemic iron overload.27 There were no 
occurrences of agranulocytosis, the most serious adverse event associated with deferiprone use, and 
there was no significant group difference in the frequency of patients having milder episodes of 
neutropenia, all of which resolved rapidly. There was a concern that the treatment of patients who did 
not have iron overload with an iron chelator might experience haematological events linked to a 
reduction of iron body stores, such as decreased serum ferritin, anaemia, and iron deficiency. 
However, although these events were seen in an increased percentage of patients taking deferiprone 
in the randomised trial, the incidence was low, the group difference was significant only for anaemia, 
none of the events was serious, and all could be managed by iron supplementation.  
A major strength of the study related to the ability to actually enrol close to 10% of all estimated 
patients with PKAN in the USA and Europe. The major limitation in the study was the lack of 
adequate pre-existing natural history data in these patients to enable an informed power calculation 
for the primary outcome related to a change in BAD score. Consequently, it is possible that the 
slower-than-expected rate of worsening in the patients treated with placebo might have affected our 
ability to achieve a significant difference in the overall intention-to-treat population.  
In summary, this study, together with previous findings, shows that the membrane-permeable iron 
chelator deferiprone achieved target engagement (lowering of iron in the basal ganglia) in patients 
with PKAN. Although the clinical endpoints were not met for the intention-to-treat population in the 
randomised trial, planned subgroup analyses provided some evidence of slowing of disease 
progression in patients with atypical disease, and the results of the extension trial indicate potential 
slowing of progression by deferiprone in the overall population as well. This study will help to shape 
the design of future trials in this ultra-orphan disease.  
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Figure Legends 
Figure 1: Profile of the main study from screening until completion at month 18. 
 
Figure 2: Marginal mean change in BAD total score over time in patients with different classes of 
PKAN in the randomised study (A) All PKAN patients. (B) Patients with atypical PKAN. (C) 
Patients with classic PKAN. Error bars represent SE. The p values for each class of PKAN were 
obtained from a mixed model for repeated measures for the comparison of the deferiprone and 
placebo groups. (D) Mean change and 95% CI from baseline in BAD total score over the main and 
extension studies (18 + 18 months) for patients in the placebo–deferiprone (left) and the 
deferiprone–deferiprone (right) groups. P values were obtained from a Student’s t test for any 
comparison between the two groups of patients or from a paired t test for any comparison within the 
same group of patients. BAD=Barry-Albright Dystonia. LOCF=last observation carried forward. 
PKAN=pantothenate kinase-associated neurodegeneration. 
 
Figure 3: Illustrative MRI data and response to deferiprone treatment (A) Images show slices from 
the conventional T2-weighted scan through the basal ganglia (left) with the R2* maps at baseline 
(centre) and at 18 months (right). The expanded anatomical regions illustrated for R2* are marked 
by the boxes on the T2-weighted scans. The quantitative R2* maps are shown with hotter colours 
representing increased iron concentrations and corresponding increased R2* values. (B) Mean (SD) 
R2* of the globus pallidus across both hemispheres for each group at each timepoint, showing the 
reduction in R2* signal in the deferiprone group that corresponds to a reduction of iron load in this 
brain region due to treatment. 
 
Figure 4: Forest plot of all secondary endpoint outcomes. Each square represents the estimated 
marginal mean difference between deferiprone and placebo for an endpoint. Mean and 95% CIs are 
standardised by the SE of the marginal mean difference. 
BAD=Barry-Albright Dystonia. FIM=Functional Independence Measure. PedsQL=Pediatric 
Quality of Life. PSQI=Pittsburgh Sleep Quality Index. UPDRS=Unified Parkinson’s Disease 
Rating Scale. 
WeeFIM=paediatric Functional Independence Measure. 
  
Table 1: Patients’ demographics, basal ganglia iron loading as assessed by MRI R2*, and BAD 
scale at baseline of the randomised and extension studies. 
 Randomised study Extension study 
 Placebo group Deferiprone 
group 
Placebo-deferiprone 
group 
Deferiprone-
deferiprone group 
Age at enrolment (years)  
N  30  59  19  43  
Mean 
(SD)  
19·2 (12·5)  20·8 (10·7)  18·2 (10·0)  22·7 (9·6)  
Range  5–55  4–52  6–40  6–47  
Age at onset (years)  
Mean 
(SD)  
7·5 (6·2)  8·4 (7·2)  8·0 (6·4)  8·2 (6·2)  
Min–max  1–23  1–29  1–23  1–19  
Sex  
Female  17 (57%)  25 (42%)  11 (58%)  16 (37%)  
Male  13 (43%)  34 (58%)  8 (42%)  27 (63%)  
Racial origin  
Asian  1 (3%)  6 (10%)  0  3 (7%)  
Black  0  2 (3%)  0  0  
Unknown  1 (3%)  0  1 (5%)  0  
White  28 (93%)  51 (86%)  18 (95%)  40 (93%)  
Basal ganglia MRI R2* (Hz)  
N  16  24  NA  NA  
Mean 
(SD)  
93·5 (31·2)  96·6 (31·6)  NA  NA  
Min–max  35·7–167·8  34·0–152·5  NA  NA  
BAD total score†  
N  28  58  19  43  
Mean 
(SD)  
16·5 (8·1)  19·6 (8·4)  20·4 (8·1)  21·3 (7·6)  
Min–max  2–31  1–32  3–30  3–30  
 
Data are number of participants (%), unless otherwise indicated. Percentages might not total 100% 
because of rounding. All patients in the extension study received only deferiprone for up to 18 
months and their data are grouped by the therapy they received during the 18 preceding months (ie, 
deferiprone or placebo), while in the randomised study. NA=not applicable. BAD=Barry-Albright 
dystonia. *BAD scores at baseline of the randomised study are based on the intent-to-treat 
population, defined as all randomised patients who (1) received at least one dose of study drug, and 
(2) provided a baseline and at least one post-baseline efficacy assessment. BAD scores at the 
baseline of the extension study are based on that study’s intent-to-treat population, which has the 
same definition as the intent-to-treat population of the randomised study. BAD data obtained at the 
end of study (month 18) visit of the randomised study was used as the baseline value of the 
extension study. 
  
Table 2: Marginal mean change in BAD score from baseline to end of study during deferiprone or 
placebo use up to 18 months in the randomised trial. 
 
 Patients (n) Marginal mean change in 
BAD score (95% CI) 
Deferiprone–
placebo mean 
difference (95% 
CI)* 
p 
value† 
 Placebo  Deferiprone  Placebo  Deferiprone    
Patients  28  58  3·99 
(2·38–5·60)  
2·48 
(1·25–3·71)  
–1·51 
(–3·19 to 0·16)  
0·076  
Classical 
PKAN  
12  29  3·72 
(1·19–6·25)  
2·91 
(1·09–4·73)  
–0·81 
(–3·68 to 2·06)  
0·570  
Atypical 
PKAN  
16  29  4·52 
(2·74–6·30)  
2·33 
(0·90–3·76)  
–2·19 
(–4·00 to –0·38)  
0·019  
 
Patients with classical PKAN are aged less than 6 years at disease onset. Patients with atypical 
PKAN are aged at least 6 years at disease onset. BAD=Barry-Albright dystonia. MMRM=mixed 
model for repeated measures. PKAN=pantothenate kinase-associated neurodegeneration. 
*Based on least squares estimates from the MMRM model.  
†p value from MMRM model. 
  
Table 3: Summary of adverse events seen in at least 10% of randomised patients who received at 
least one dose of the study drug. 
 Placebo (n=30) Deferiprone 
(n=58) 
p value 
(Fisher’s 
exact test)  
Dystonia  14 (47%)  25 (43%)  0·823  
Pyrexia  13 (43%)  16 (28%)  0·157  
Serum ferritin decreased  5 (17%)  19 (33%)  0·134  
Headache  9 (30%)  13 (22%)  0·448  
Nasopharyngitis  6 (20%)  11 (19%)  1·00  
Anaemia  0 (0%)  12 (21%)  0·007  
Condition aggravated  9 (30%)  10 (17%)  0·183  
Pain in extremity  4 (13%)  10 (17%)  0·764  
Cough  5 (17%)  10 (17%)  1·00  
Vomiting  8 (27%)  9 (16%)  0·258  
Iron deficiency  3 (10%)  9 (16%)  0·744  
Oropharyngeal pain  3 (10%)  9 (16%)  0·744  
Upper respiratory tract infection  4 (13%)  8 (14%)  1·00  
Arthralgia  1 (3%)  8 (14%)  0·158  
Bronchitis  2 (7%)  7 (12%)  0·712  
Laceration  3 (10%)  6 (10%)  1·00  
Ear pain  3 (10%)  1 (2%)  0·113  
Abdominal pain upper  5 (17%)  4 (7%)  0·264  
Constipation  4 (13%)  2 (3%)  0·175  
Diarrhoea  3 (10%)  4 (7%)  0·686  
Gastrointestinal infection  3 (10%)  3 (5%)  0·406  
Freezing phenomenon  3 (10%)  0  0·037  
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Figure 4: Forest plot of all secondary endpoint outcomes. 
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Supplement 
 
Methods 
 
Participants 
 
Recruitment was via the centers’ own patients, referral from other neurologists and by 
posting information on the NBIA Disorders Association website. 
 
Full list of inclusion and exclusion criteria: 
 
Inclusion Criteria 
1. Males or females 4 years of age and older at screening visit 
2. Have PKAN, confirmed by genetic testing 
3. BAD total score ≥ 3 at the screening visit 
4. Patients who have Deep Brain Stimulation (DBS) systems or baclofen pumps in place will 
be eligible for the study, but they must have had a stable setting for at least two months prior 
to the screening visit; Enrollment of non-DBS patients will be given priority in order to 
ensure the majority can undergo imaging 
5. Informed consent/assent obtained before any study-related activities 
6. Ability and willingness to adhere to the protocol including appointments and evaluation 
schedule 
7. Sexually active female patients of childbearing potential must have a negative pregnancy 
test result at Screening Visit. In addition, if applicable, females of childbearing potential must 
use an effective method of contraception according to local requirements, OR have had a 
tubal ligation, OR have had a hysterectomy, OR participates in a non-heterosexual 
lifestyle, OR have a male sexual partner has been sterilized 
8. If the patient is a heterosexual sexually-active male, patient must confirm, in writing, that 
he and/or his female partner will use an effective method of contraception according to local 
requirements for the length of the trial and for 30 days following completion of the study or 
early termination 
Exclusion Criteria 
1. Evidence of iron deficiency defined by Fe:TIBC ratio <15%, or serum ferritin <12 ng/mL 
2. Treatment with deferiprone in the past 12 months 
3. Previous failure of treatment with deferiprone, or previous discontinuation of treatment 
with deferiprone due to adverse events 
4. Conditions known to contraindicate the use of deferiprone (history of agranulocytosis or 
recurrent episodes of neutropenia) 
5. A serious, unstable illness during the past 3 months before screening visit including but not 
limited to: hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, 
neurologic or immunologic disease  
6. Evidence of abnormal liver or renal function (serum liver enzyme level(s) > 3 times upper 
limit of normal at screening) or abnormal creatinine levels at screening visit  
7. Disorders associated with neutropenia (ANC < 1.5 x 109/L) or thrombocytopenia (platelet 
count < 50 x 109/L) in the 12 months preceding the initiation of the study medication. 
Exception: for patients whose neutropenia was attributed by the treating physician to episodes 
of infection or to drugs associated with a decline in the neutrophil count and in whom the 
ANC has fully recovered at the screening visit 
8. History of malignancy 
9. QTcF interval > 450 msec 
10. HIV positive 
11. Myocardial infarction, cardiac arrest or cardiac failure within 1 year before screening visit 
12. Bowel disease causing malabsorption 
13. History of alcohol or drug abuse 
14. Treatment with an investigational drug within 30 days or 5 half-lives (whichever is 
longer) preceding the baseline visit 
15. Currently taking iron chelators 
16. Pregnant, nursing females and females of childbearing potential who are heterosexually 
active and unwilling, or unable, to use an acceptable method of contraception according to 
local requirements 
17. Males who are sexually active and unwilling, or unable, to use an acceptable method of 
contraception according to local requirements 
18. History or presence of hypersensitivity or idiosyncratic reaction to deferiprone 
19. Patients (or when applicable parent or patients’ legal representatives) with a mental 
incapacity, unwillingness or language barriers precluding adequate understanding or 
cooperation 
20. Any condition that, in investigator’s opinion, would adversely affect the patient’s ability 
to complete the study or its assessments 
21. Baclofen pump placement less than two months prior to the screening visit 
22. Current and ongoing participation in other clinical studies 
 
Procedures 
In both trials, dosage was based on milligrams of DFP per kilogram of body weight, starting 
at 5 mg/kg b.i.d. and titrated up to 15 mg/kg b.i.d. by Week 12. In TIRCON2012V1, patients 
in the control group received a matching volume of placebo during the same time periods. 
All efficacy measures were administered at baseline (except for the PGI-I, which is a measure 
of change from baseline), months 6, 12, and 18 or early termination. Iron levels in the globus 
pallidus were measured by MRI-R2* in a subset of patients (those without a DBS device and 
able to undergo an MRI scan) at baseline and Month 18. MRI scans were conducted 
according to a standardized imaging protocol, and the images were sent to central reading by 
radiologists who were blinded to treatment. None of the MRI-R2* results were disclosed by 
the radiologist until the last patient completed the trial. 
 
Information was also collected on the use of concomitant medications, with particular 
attention on any changes in drugs or devices used to relieve symptoms of dystonia. Patients 
had weekly hematology tests to monitor their absolute neutrophil count (ANC). Patients with 
two consecutive samples with ANC < 1.5×109/L were withdrawn from the study. 
To reduce the confounding effects of concomitant therapies on the assessment of treatment, 
patients with recent or expected changes in therapies that have the potential to affect dystonia 
symptoms were excluded from enrolment. 
 
  
Results 
Dystonia medications taken on a regular schedule at baseline 
Suppl. Table 1: Dystonia medications taken on a regular schedule at baseline 
 
Medication Placebo (N=30) 
N subjects (%) 
DFP (N=58) 
N subjects (%) 
Baclofen 14 (46.7) 27 (46.6) 
Trihexyphenidyl 9 (30.0) 25(43.1) 
Clonazepam 7 (23.3) 12 (20.7) 
Diazepam 4 (13.3) 5 (8.6) 
Levodopa 3 (10.0) 5 (8.6) 
Pantothenic acid 3 (10.0) 3 (5.2) 
Biperiden 1 (3.3) 3 (5.2) 
Tetrabenazine 1 (3.3) 3 (5.2) 
Tizanidine 1 (3.3) 3 (5.2) 
Clonidine 1 (3.3) 1 (1.7) 
Lorazepam 0 (0.0) 2 (3.4) 
Botulinum toxin type A 1 (3.3) 0 (0.0) 
Clozapine 0 (0.0) 1 (1.7) 
Gabapentin 0 (0.0) 1 (1.7) 
Haloperidol 0 (0.0) 1 (1.7) 
Tiapride 0 (0.0) 1 (1.7) 
 
  
Further analyses regarding a possible ceiling effect There were proportionally more patients 
with baseline BAD score close to the maximum score of 32 being randomized to the 
deferiprone treatment group. To investigate whether a “ceiling effect” might account for the 
differences observed in BAD in response to treatment with deferiprone, the mITT data were 
re-analyzed after excluding all patients that would have had the potential to experience a 
ceiling effect. Using the cut-off of 27 for the baseline BAD score, it is evident that the 
difference in response to treatment is not lessened by the dropping of patients with a cut-off 
of 27, even though, as would be expected, fewer subjects lessens the level of statistical 
significance, as shown in Suppl. Table 2a. 
 
Suppl. Table 2a: Main MMRM analysis excluding baseline BAD > 27 in the TIRCON study 
Subpopulation Placebo DFP DFP – 
Placebo 
Marginal 
Mean 
Difference 
(95% CI) 
P value 
N Marginal 
Mean Change 
(SE) 
N Marginal 
Mean Change 
(SE) 
All patients 28 3.99 (0.82) 58 2.48 (0.63) -1.51 
(-3.91, 0.16) 
0.0761 
Baseline BAD 
<=27 
26 4.62 (0.96) 42 3.07 (0.81) -1.55 
(-3.47, 0.37) 
0.1114 
 
 
 
To further investigate the impact of ceiling effect, a reanalysis of the data was conducted 
using 3 different strata of baseline values. To avoid the risk of bias in selection of what might 
constitute suitable cut-off points, we let the data select the points by choosing tertiles of 
baseline BAD. The MMRM modelling performed for the primary analysis was repeated for 
each subgroup defined by the tertiles of the baseline BAD score: ≤13, 13-24, >24. The results 
are summarized in Suppl. Table 2b below. The analysis reveals that the treatment effect as 
measured by the marginal mean difference between DFP and placebo was observed for each 
subgroup, indicating benefit of deferiprone over placebo regardless of the baseline BAD 
level, and, numerically, the largest observed difference is in those with no potential for a 
ceiling effect. Weaker levels of significance are attributed to smaller numbers of subjects in 
each group, compared to the full cohort. 
 
Suppl. Table 2b: Main MMRM analysis by subgroups based on the tertiles of baseline BAD 
 
  
Correlation between the BAD scale and the PGI-I 
The change of PGI-I at completion of 18 months of study therapy was included as a co-
primary endpoint based on a request by a regulatory agency. At Month 18, the LSmean 
scores were 4.66 for placebo and 4.55 for DFP, with no significant group difference 
(p=0.7279) indicating that, overall, patients did not detect either an improvement or a 
worsening in their condition from baseline. 
 
To the best of our knowledge, the PGI-I had not been previously used in a prospective study 
in patients with NBIA and no data are currently available on its value for identifying the 
clinical significance of other study measures. To that extent, the TIRCON study provides 
valuable data for the determination, if a correlation existed between a measurement of disease 
progression such as the BAD score and the PGI-I. 
 
Suppl. Figure 1 shows the correlation between the PGI-I and the change in BAD score at 
Month-18. The analysis reveals a weak correlation (r = 0.29), in which < 10% of the PGI-I 
variation can be explained by the change in BAD (r square < 0.1), indicating the PGI-I is not 
an adequate tool for assessment in PKAN over an 18 month period. 
 
  
Suppl. Figure 1. Correlation between change from baseline in BAD score and PGI-I score at 
Month 18. 
 
  
WeeFIM assessments 
The WeeFIM, which rates 18 activities of daily living in terms of how much assistance is 
needed, scores each item from 1 (total dependence) to 7 (complete independence), and 
generates a global score that ranges from 18 to 126. Thus, a decrease in score indicates 
worsening. The global score for the placebo group worsened by 2.40 points while that for the 
DFP group improved by 4.91 points, although the difference was not significant (p=0.2026). 
For the subscale scores, a significant difference in favor of DFP (p=0.0324) was seen for 
cognition. Treatment group differences in the domain of cognition reached significance in 
favor of DFP for problem solving (p=0.0258) and social interaction (p=0.0414), and 
approached significance for memory (p=0.0574). Suppl. Figure 2 displays a polar graph for 
each treatment group of all the elements contributing to the global WeeFIM score. For the 
placebo group, there was either worsening or lack of improvement in all measures; for the 
DFP group, improvement was seen for 4 of the 5 cognitive components (comprehension, 
social interaction, problem solving, and memory) and no change on the fifth (expression) but 
worsening or lack of improvement for the items in the self-care and mobility domains. 
 
  
Suppl. Figure 2. Polar graph of WeeFIM scores. The blue lines represent scores at baseline, 
and the red lines represent scores at Month 18. Values that are closer to the center indicate 
lower functioning, so a red line that is inside the blue line indicates worsening, a red line that 
overlaps the blue line indicates no change, and a red line that is outside the blue line indicates 
improvement. 
  
Safety 
Regarding safety, DFP was well tolerated and rates of adverse events were similar between 
the treatment groups except for anemia, which was seen more frequent in DFP-treated 
patients than in placebo patients. An overview of the different categories of safety findings 
during the randomized phase of the studies is shown in Suppl. Table 3. 
 
 
  
Changes in BAD score in the TIRCON and TIRCON-Extension studies 
Over the 18 months of the extension study, there was no significant difference in the change 
in BAD score for patients who had been on DFP from the start (1.9±0.5 points in the first 18 
months vs 1.4±0.4 points in the second 18 months, p=0.2684) while there was significantly 
less worsening in the placebo-DFP group (4.4±1.1 points when they were receiving placebo 
vs 1.4±0.9 points when they were receiving DFP, p=0.0206) (Suppl. Table 4). Placebo-DFP 
group represents the patients who received placebo during the first 18 months and 
deferiprone during the subsequent 18 months. DFP-DFP group represent the patients who 
received deferiprone during the 36 months of both trials. Classical PKAN are patients with 
age at onset of disease < 6 years. Atypical PKAN are patients with age at onset of disease ≥ 6 
years. 
 
